Evidence map›Paper›PMID 37284049›Full record

ArticleEuropean urology open science2023

Oligometastasis in Prostate Cancer: Can We Learn from Those "Excluded" from a Phase 2 Trial?

Rachel M Glicksman, Vanessa Murad, Anna T Santiago, Zhihui Liu, Matthew Ramotar, Ur Metser, Alejandro Berlin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Rachel M GlicksmanDepartment of Radiation Oncology, University of Toronto, Toronto, Canada.
Vanessa MuradJoint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Canada.
Anna T SantiagoDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Zhihui LiuDepartment of Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Matthew RamotarRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Ur MetserJoint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Canada.
Alejandro BerlinDepartment of Radiation Oncology, University of Toronto, Toronto, Canada.
University Health Network · CAPrincess Margaret Cancer Centre · CAUniversity of Toronto · CAWomen's College Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted and previously published a phase 2 trial of metastasis-directed therapy (MDT) in men with recurrence of prostate cancer at a low prostate-specific antigen level following radical prostatectomy and postoperative radiotherapy. All patients had negative conventional imaging and underwent prostate-specific membrane antigen (PSMA) positron emission tomography (PET). Patients without visible disease ( Patient summary: In men with prostate cancer with rising PSA levels following surgery and radiation, a newer type of scan called PSMA-PET (prostate-specific membrane antigen positron emission tomography) can be used to characterize and differentiate the patterns of recurrence, and inform future cancer outcomes.

Indexed as

Metastasis-directed therapyOligometastasisPositron emission tomographyProstate cancerProstate-specific membrane antigen

Identifiers

PMID37284049
PMCPMC10240507
OpenAlexW4367675055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.